and intravenous (IV) formulations of sabirnetug in healthy volunteers. Weekly SC administration of sabirnetug was well-tolerated with systemic exposure supporting further clinical development.

Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...

I graduated from the University of Edinburgh in 1991 and undertook a period of postgraduate research in Dundee examining the effects of hypoxia, hypercapnia and vasoactive peptides on the pulmonary ...